The company has successfully secured financing in an oversubscribed funding round.

“This funding will propel our efforts in establishing key partnerships and driving SiPore technology to market. We are thrilled to have the backing of our investors as we move closer to providing effective solutions for obesity and diabetes management,” says Sana Alajmovic, Sigrid’s Co-Founder and CEO.

Amidst concerns about obesity and diabetes, the demand for effective, non-drug therapies is evident.”

The funds will be instrumental in accelerating the commercialization of SiPore across diverse markets, including medical devices, food supplements, veterinary, and oral health. SiPore21, the company’s flagship product, is currently undergoing SHINE clinical trials as a natural, non-drug solution for prediabetes progression and weight control. Administered orally, SiPore21 utilizes a carefully engineered, mesoporous silica mineral to prevent digestive enzymes from breaking down carbohydrates and fats, offering a promising alternative to pharmaceutical methods.

“We’re pleased that Sigrid Therapeutics’ recent share offering was oversubscribed by an impressive 50%. In today’s challenging financial climate, this achievement underscores the company’s quality and potential. Amidst concerns about obesity and diabetes, the demand for effective, non-drug therapies is evident. This success mirrors investor confidence and Sigrid’s commitment to pioneering drug-free solutions,” says Lars Molinder, financial adviser to Sigrid Therapeutics.

Photo of Sana Alajmovic: Sigrid Therapeutics